Dr. Lori Rink, Fox Chase Cancer Center, and Dr. Inga-Marie Schaefer, Brigham & Women’s Hospital, are two researchers who are making discoveries in their respective laboratories to uncover the unique biomarkers in GIST that will be future drug targets.
Become a GEM today! Help us continue our programs and services for GIST patients by giving a monthly recurring donation. Every little bit helps us to further research and support GIST patients and caregivers.
In our LRG community, we’ve seen many examples of GISTer family planning but also women who have found out they had GIST while they were pregnant. Here are some helpful resources
In a recent study, researchers at University of California San Diego School of Medicine identified new therapeutic targets that could lead to new treatment options for patients. The study, published in the February 18, 2021 online edition of Oncogene, found that specific cell-to-cell communication influences GIST biology and is strongly associated with cancer progression and metastasis.
Dr. Annes reviewed the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. Here is a Resource list for GIST and other cancers.
Understanding the role of mutations and biomarker testing is one of most important things patients must learn. Uncovering the driving force behind each individual’s tumors is not just important, it is critical. This video talks about why it's important.
It is time to stop talking and take action to assure patients get tested. The goal of the 'It's Time' campaign is to increase and improve the understanding of biomarker testing in the cancer community and get patients tested.
NCCN repost - Leading cancer and infectious disease experts offer preliminary advice on how to quickly, safely, and efficiently protect vulnerable patients from COVID-19; with more updates to come.
